Multiple endocrine neoplasia type 2 cost-effectiveness of therapy

Jump to navigation Jump to search

Multiple endocrine neoplasia type 2 Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Multiple endocrine neoplasia type 2 from other Diseases

Epidemiology & Demographics

Risk Factors

Screening

Natural History, Complications & Prognosis

Diagnosis

Diagnostic Criteria

History & Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Multiple endocrine neoplasia type 2 cost-effectiveness of therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Multiple endocrine neoplasia type 2 cost-effectiveness of therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Multiple endocrine neoplasia type 2 cost-effectiveness of therapy

CDC on Multiple endocrine neoplasia type 2 cost-effectiveness of therapy

Multiple endocrine neoplasia type 2 cost-effectiveness of therapy in the news

Blogs on Multiple endocrine neoplasia type 2 cost-effectiveness of therapy

Directions to Hospitals Treating Multiple endocrine neoplasia type 2

Risk calculators and risk factors for Multiple endocrine neoplasia type 2 cost-effectiveness of therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]

Overview

Cost-effective management of multiple endocrine neoplasia type 2 include targeted therapy, prophylactic thyroidectomy and restricted molecular screening.

Cost-Effectiveness of Therapy

Methods for Cost Effectiveness of the Therapy

References

  1. Chang CF, Yang WS, Su YN, Wu IL, Chang TC (2009). "Mutational spectrum of multiple endocrine neoplasia type 2 and sporadic medullary thyroid carcinoma in taiwan". J Formos Med Assoc. 108 (5): 402–8. doi:10.1016/S0929-6646(09)60084-X. PMID 19443294.
  2. Cohen MS, Phay JE, Albinson C, DeBenedetti MK, Skinner MA, Lairmore TC; et al. (2002). "Gastrointestinal manifestations of multiple endocrine neoplasia type 2". Ann Surg. 235 (5): 648–54, discussion 654-5. PMC 1422490. PMID 11981210.
  3. "CREST Cost-effectiveness of targeted and population based screening strategies for multiple endocrine neoplasia type 2B" (PDF).

​​​

Template:WikiDoc Sources